Consensus statement on antimicrobial treatment of odontogenic bacterial infections;Documento de consenso sobre el tratamiento antimicrobiano de las infecciones bacterianas odontogénicas

Medicina Oral, Patologia Oral y Cirugia Bucal

Volumn 9, Issue 5, 2004, Pages 363-376

  Bascones Martínez, Antonio ^a   Aguirre Urízar, José Manuel ^b   Bermejo Fenoll, Ambrosio ^c   Blanco Carrión, Andrés ^d   Gay Escoda, Cosme ^e   González Moles, Miguel Ángel ^f   Gutiérrez Pérez, José Luis ^g   Jiménez Soriano, Yolanda ^h   Liébana Ureña, José ^f   López Marcos, Joaquín Francisco ⁱ   Maestre Vera, Juan Ramón ^j   Perea Pérez, Evelio José ^g   Prieto Prieto, José ^a   De Vicente Rodríguez, Juan Carlos ^k  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^b UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

^c UNIVERSITY OF MURCIA   (Spain)

^d UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

^e UNIVERSITY OF BARCELONA   (Spain)

^f UNIVERSITY OF GRANADA   (Spain)

^g UNIVERSITY OF SEVILLE   (Spain)

^h UNIVERSITY OF VALENCIA   (Spain)

ⁱ UNIVERSITY OF SALAMANCA   (Spain)

^j UNIVERSIDAD ALFONSO X EL SABIO   (Spain)

^k UNIVERSITY OF OVIEDO   (Spain)

more..

Author keywords

Amoxicilin; Antibiotics; Antimicrobial agents; Classification; Clawlanic acid; Diagnose; Odontogenic infections; Odontogenic microorganisms; Resistance; Treatment

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; ANTIBIOTIC AGENT; AZITHROMYCIN; CEPHALOSPORIN DERIVATIVE; CHLORHEXIDINE; CLARITHROMYCIN; CLINDAMYCIN; DOXYCYCLINE; ERYTHROMYCIN; LINCOSAMIDE DERIVATIVE; MACROLIDE; METRONIDAZOLE; NITROIMIDAZOLE DERIVATIVE; ORNIDAZOLE; PENICILLIN G; TINIDAZOLE;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL INFECTION; CONSENSUS; DISEASE CLASSIFICATION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG INDICATION; DRUG MEGADOSE; DRUG TOLERABILITY; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HUMAN; MICROBIOLOGY; ODONTOLOGY; PRACTICE GUIDELINE; TOOTH INFECTION; TREATMENT INDICATION; CONFERENCE PAPER; CONSENSUS DEVELOPMENT; MOUTH DISEASE;

BACTERIAL INFECTIONS; HUMANS; MOUTH DISEASES;

EID: 20244375556     PISSN: 16984447     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (62)

1. Machuca M, Espejo J, Gutiérrez L, Herrera J. Análisis de la prescripción antibiótica en una farmacia comunitaria. Pharm Care Esp 2000;2:411-9.
2. Intercontinental Marketing Services Ibérica, S.A. 2003; Madrid. España.
3. Beck JD, Pankow J, Tyroler HA, Offenbacher S. Dental infections and atherosclerosis. Am Heart J 1999;138:528-33.
4. Offenbacher S, Beck J. Periodontitis: A potential risk factor for spontaneous preterm birth. Compend Contin Educ Dent 1998;19:32-9.
5. Loesche WJ. Association of the oral flora with important medical diseases. Curr Opin Periodontol 1997;4:21-8.
6. Gay-Escoda C, Berini Aytés L, eds. Tratado de Cirugía Bucal. Tomo I. Madrid: Ergon; 2004.
7. Maestre JR. Infecciones bacterianas mixtas de la cavidad oral. Enferm Infecc Microbiol Clin 2002;20:98-101.
8. Armitage GC. Development of a classification system for periodontal diseases and conditions. Ann Periodontol 1999;4:1-6.
9. Caton JF. Periodontal diagnosis and diagnostic aids. En: World workshop in clinical periodontics. Princeton, NJ: American Academy of Periodontology; 1989. p. 1-22.
10. Valle Rodríguez JL, Gómez-LusCentelles ML, Prieto Prieto J, Liébana Ureña J. Composición y ecología de la microbiota oral. En: Liébana Ureña J. eds. Microbiología oral. Madrid: Interamericana McGraw-Hill; 1995. p. 402-7.
11. Chow AW. Infections of the oral cavity, neck, and head. En: Mandell GL, Bennett JE, Dolin R, eds. Principles and Practice of infectious diseases. 5th edition. Philadelphia: Churchill Livingstone; 2000. p. 689-701.
12. Valenti WM, Trudell RG , Bentley DW. Factors predisposing to oropharyngeal colonization with gramnegative bacilli in the aged. N Engl J Med 1978;298:1108.
13. Brook I, Frazier EH, Gher ME. Aerobic and anaerobic microbiology of periapical abscess. Oral Microbiol Immunol 1991;6:123-5.
14. Cianco SG. Antiseptics and antibiotics as chemotherapeutic agents for periodontitis management. Compend Contin Educ Dent 2000;21:59-62.
15. Slots J, Jorgensen MG. Efficient antimicrobial treatment in periodontal maintenance care. J Am Dent Assoc 2000;131:1293-304.
16. Loesche WJ, Grossman NS. Periodontal disease as a specific, albeit chronic, infection: diagnosis and treatment. Clin Microbiol Rev 2001;14:727-52.
17. Jorgensen MG, Slots J. Practical antimicrobial periodontal therapy. Compend Contin Educ Dent 2000;21:111-6.
18. Siqueira JF. Endodontic infections: Concepts, paradigms, and perspectives. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2002;94:281-93.
19. Ciancio SG, Van Winkelhoff AJ. Antibiotics in periodontal therapy. En: Newman MG, Winkelhoff AJ, eds. Antibiotics and antimicrobial use in dental practice. Illinois: Quintessence Publishing Co, Inc; 2001.
20. Quinteros M, Delgado E, Sánchez MA, Berini L, Gay-Escoda C. Estudio microbiológico de la periimplantitis. Presentación de 9 casos clínicos. Av Periodoncia Implantol Oral 2000;12:137-50.
21. Liñares J, Martín-Herrero JE. Bases farmacomicrobioló gicas del tratamiento antibiótico de las enfermedades periodontales y periimplantarias. Av Odontoestomatol 2003;(especial):23-33.
22. Walker CB. The acquisition of antibiotic resistance in the periodontal pathogens. Periodontol 2000 1996;10:79-88.
23. Herrera D, Van Winkelhoff AJ, Dellemijn-Kippuw N, Winkel EG, Sanz M. Beta-lactamase producing bacteria in the subgingival microflora of adult patients with periodontitis. A comparison between Spain and the Netherlands. J Clin Periodontol 2000;27:520-5.
24. Van Winkelhoff AJ, Winkel EG, Barendregt D, Dellemijn-Kippuw, Stijne A, Van der Velden U. Beta-lactamase producing bacteria in adult periodontitis. J Clin Periodontol 1997;538-43.
25. Alcaide F, Liñares J, Pallares R, Carratala J, Benítez MA, Gudiol F, et al. In vitro activities of 22 beta-lactam antibiotics against Penicillin-Resistant and Penicillin-susceptible viridans group streptococci isolated from blood. Antimicrob Agents Chemother 1995;39:2243-7.
26. Ioannidou S, Tassios PT, Kotsovili-Tseleni A, Foustoukou M, Legakis NJ, Vatapoulos A, et al. Antibiotic resistance rates and macrolide resistance phenotypes of viridans group streptococci from the oropharynx of healthy Greek children. Int J Antimicrob Agents 2001;17:195-201.
27. Doern GV, Ferraro MJ, Brueggemann AB, Ruoff KL. Emergence of high rates of antimicrobial resistance among viridans group streptococci in the United States. Antimicrob Agents Chemother 1996;40:891-4.
28. Aracil B, Miñanbres M, Oteo J, Torres C, Gómez-Garces JL, Alos JI. High prevalence of erythromycin-resistant and clindamycin-susceptible (M phenotype) viridans group streptococci from pharyngeal samples: a reservoir of mef genes in commensal bacteria. J Antimicrob Chemother 2002;48:587-95.
29. Prieto J, Martín-Herrero JE, García-Rey C. Relación entre consumo de antibióticos y selección de resistencia en el género Streptococcus. Medicina Preventiva 2002;8:23-30.
30. Bascones A, Manso FJ. Tratamiento de las infecciones orofaciales de origen bacteriano. En: Bascones A, Manso FJ, eds. Infecciones orofaciales. Diagnostico y tratamiento. Madrid: Avances Médico-Dentales; 1994. p. 89-116.
31. Kuriyama T, Karasawa T, Nakagawa K, Saiki Y, Yamamoto E, Nakamura S. Bacteriologic features and antimicrobial susceptibiliry in isolates from orofacial odontogenic infections. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2000;90:600-8.
32. Legg JA, Wilson M. The prevalence of beta-lactamase producing bacteria in subgingival plaque and their sensitivity to Augmentin. Br J Oral Maxillofac Surg 1990;28:180-4
33. Heimdahl A, Von Konow L, Nord CE. Beta-lactamase-producing Bacteroides species in the oral cavity in relation to penicillin therapy. J Antimicrob Chemother 1981;8:225-9.
34. Kinder SA, Holt SC, Korman KS. Penicillin resistance in subgingival microbiota associated with adult periodontitis. J Clin Microbiol 1986;23:1127-33.
35. Aldridge KE, Ashcraft D, Cambre K, Pierson CL, Jenkins SG, Rosemblatt JE. Multicenter survey of the changing in vitro antimicrobial susceptibilities of clinical isolates of Bacteroides fragilis group, Prevotella, Fusobacterium, Porphyromonas, and Peptostreptococcus species. Antimicrob Agents Chemother 2001;45:1238-43
36. Fosse T, Madinier I, Hitzig C, Charbit Y. Prevalence of beta-lactamase-producing strains among 149 anaerobic gram-negative rods isolated from periodontal pockets. Oral Microbiol Immunol 1999;14:352-7.
37. Wexler HM, Molitoris E, Molitoris D. Susceptibility testing of anaerobes: old problems, new options?. Clin Infect Dis 1997;25:275-8.
38. Brook I, Gober AE. Emergence of beta-lactamase-producing aerobic and anaerobic bacteria in the oropharynx of children following penicillin chemotherapy. Clin Pediatr 1984;23:338-41.
39. Turner K, Nord CE. Emergence of beta-lactamase producing microorganisms in the tonsils during penicillin treatment. Eur J Clin Microbiol 1986;5:399-404.
40. Muñoz Bellido JL, Alonso MA, Gutiérrez MN. Penicilinas. En: García Sanchez JE, López R, Prieto J, eds. Antimicrobianos en Medicina. Barcelona: Prous Science; 1999. p. 41-71.
41. Marín M, Gudiol F. Antibióticos betalactámicos. Enferm Infecc Microbiol Clin 2003;21:42-5.
42. Abu-Fanas SH, Dricker DB, Hull PS. Amoxicillin with clavulanate acid and tetracycline in periodontal therapy. J Dent 1991;19:97-9.
43. Todd PA, Benfield P. Amoxicillin/clavulanic acid. An update of its antimicrobial activity, pharmacokinetic properties and therapeutic use. Drugs 1990;39:264-307.
44. Kaye CM, Allen A, Perry S, McDonagh M, Davy M, Storm K, et al. The clinical pharmacokinetics of a new pharmacokinetically enhanced formulation of amoxicillin/clavulanate. Clin Ther 2001;23:578-84.
45. Jacobs MR. How can we predict bacterial eradication?. Int J Infect Dis 2003;7:S13-20.
46. Martínez Lacasa J, Jiménez J, Ferrás V, García-Rey C, Bosom M, Sola-Morales O, et al. A Double Blind, Placebo-Controlled, Randomised, Comparative Phase III Clinical Trial of Pharmacokinetically Enhanced Amoxicillin/Clavulanate 2000/125, as Prophylaxis or as Treatment vs Placebo for Infectious and Inflammatory Morbidity after Third Mandibular Molar Removal (TMR). 43rd Annual ICAAC Chicago. September 2003.
47. Garau J, Twynholm M, García-Méndez E, Siquier B, Rivero A and the 557 Clinical Study Group. Oral pharmacokinetically enhanced co-amoxiclav 2000/125 mg, twice daily, compared with co-amoxiclav 875/125 mg three times daily, in the treatment of community-acquired pneumonia in European adults. J Antimicrob Chemother 2003;52:826-36.
48. Schrag SJ, Peña C, Fernández J. Effect of short-course, high-dose amoxicillin therapy on resistant pneumococcal carriage. A randomized trial. JAMA 2001;286:49-56.
49. Marín M, Gudiol F. Antibióticos betalactámicos. Enferm Infecc Microbiol Clin 2003;21:42-5
50. Van Winkelhoff AJ, Herrera González D, Winkel EG, Dellemijn-Kippuw N, Vandenbroucke-Grauls CM, Sanz M. Antimicrobial resistance in the subgingival microflora in patients with adult periodontitis. A comparison between The Netherlands and Spain. J Clin Periodontol 2000;27:79-86.
51. Pérez Trallero E, Iglesias L. Tetraciclinas, sulfamides y metronidazol. Enferm Infecc Microbiol Clin 2003;21:520-9.
52. Gómez García AC, Blanco Roca MT, Morán Domínguez FJ. Nitroimidazoles. En: García Sánchez JE, López R, Prieto J, eds. Antimicrobianos en Medicina. Barcelona. Prous Science; 1999. p. 377-82.
53. Koeth LM, Good CE, Appelbaum PC. Surveillance of susceptibility patterns in 1297 European and US anaerobic and capnophilic isolates to co-amoxiclav and five other antimicrobial agents. J Antimicrob Chemother 2004; Advance Access published May 5.
54. Turner PJ, Edward JR. A compilation of studies assessing the in vitro activity of meropenem and comparators in 84 laboratories throughout Europe. Clin Microbiol Infect 1997;3:32-50.
55. Rodríguez-Avial I, Rodriguez Avial C, Culebras E. Distribution of mef(A) and erm(B) genes in macrolide-resistant blood isolates of viridans group streptococci. J Antimicrob Chemother 2001;47:727-8
56. Mensa J, Gatell JM, Jiménez de Anta MT, Prats G, Domínguez-Gil A, eds. Guía de terapéutica antimicrobiana 2002. Barcelona: Masson.
57. Gordon JM, Walker CB. Current status of systemic antibiotic usage in destructive periodontal disease. J Periodontol 1993;64:760-71
58. Eick S, Pfister W, Fiedler D, Straube E. Clindamycin promotes phagocytosis and intracelluar killing of periodontopathogenic bacteria by crevicular granulocytes: an in vitro study. J Antimicrob Chemother 2000;46:583-8
59. Mensa J, García-Vázquez E, Vila J. Macrólidos, cetólidos y estreptograminas. Enferm Infecc Microbiol Clin 2003;21:200-8.
60. Pérez-Trallero E, Fernández-Mazarrasa C, García-Rey C, Bouza E, Aguilar L, García-de-Lomas J, et al, Spanish Surveillance Group for Respiratory Pathogens. Antimicrobial susceptibilities of 1,684 Streptococcus pneumoniae and 2,039 Streptococcus pyogenes isolates and their ecological relationships: results of a 1-year (1998-1999) multicenter surveillance study in Spain. Antimicrob Agents Chemother 2001;45:3334-40.
61. Pérez-Trallero E, Vicente D, Montes M, Marimón JM, Piñeiro L. High proportion of pharyngeal carriers of comensal streptococci resistant to erythromycin in Spanish adults. J Antimicrob Chemother 2001;48:225-9.
62. Prieto J, Maestre JR. Tratamiento de las infecciones de etiología mixta. En: Bascones A, Perea EJ, eds. Infecciones orofaciales. Volumen 2. Madrid: Dentisnet; 2003.